{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:08:39Z","timestamp":1790856519652,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the long\u2010term clinical and imaging efficacy of etanercept in patients with early, active nonradiographic axial spondyloarthritis (SpA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients who satisfied the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial SpA (but not the modified New York radiographic criteria), with symptom duration &gt;3 months to &lt;5 years, and who were unresponsive to \u22652 nonsteroidal antirheumatic drugs (NSAIDs) received double\u2010blind etanercept 50 mg\/week or placebo for 12 weeks, followed by open\u2010label etanercept 50 mg\/week to week 104. Clinical, magnetic resonance imaging (MRI; Spondyloarthritis Research Consortium of Canada [SPARCC] scores), and safety outcomes at 104 weeks were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 215 randomized patients (etanercept: n\u2009=\u2009106; placebo: n\u2009=\u2009109), 205 entered the study (etanercept\/etanercept: n\u2009=\u2009100; placebo\/etanercept: n\u2009=\u2009105) and 169 completed the open\u2010label period (etanercept\/etanercept: n\u2009=\u200983; placebo\/etanercept: n\u2009=\u200986). At week 104, 61 of 81 (75%), 49 of 81 (61%), 48 of 80 (60%), and 57 of 81 (70%) patients who received etanercept throughout the trial achieved ASAS20, ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease, and Bath Ankylosing Spondylitis Disease Activity Index criteria for 50% improvement (BASDAI 50) scores, respectively (observed). From baseline to week 104, continued improvements in clinical outcomes (ASDAS\u2013C\u2010reactive protein: \u22121.5 and \u22121.7; BASDAI: \u22123.3 and \u22123.8 [last observation carried forward]), and SPARCC MRI scores (sacroiliac joint: \u22126.0 and \u22123.4; spinal: \u22122.1 and \u22120.8 [observed]) were seen in patients receiving etanercept\/etanercept and placebo\/etanercept. During the study, 8% in the etanercept\/etanercept group and 7% in the placebo\/etanercept group had serious adverse events; no new safety signals were seen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with early, active nonradiographic axial SpA and an inadequate response to at least 2 NSAIDs demonstrated improvement in clinical and imaging outcomes that were sustained through 104 weeks of etanercept treatment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23276","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T16:32:47Z","timestamp":1494261167000},"page":"1590-1598","source":"Crossref","is-referenced-by-count":33,"title":["Effects of Long\u2010Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104\u2010Week Results From a Randomized, Placebo\u2010Controlled Study"],"prefix":"10.1002","volume":"69","author":[{"given":"Maxime","family":"Dougados","sequence":"first","affiliation":[{"name":"Paris\u2010Descartes University, H\u00f4pital Cochin Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2010 Universit\u00e4tsmedizin Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[{"name":"Instituto de Rehabilitaci\u00f3n Psicof\u00edsica de Buenos Aires Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lenaerts","sequence":"additional","affiliation":[{"name":"Reuma\u2010Instituut Hasselt Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"van den Bosch","sequence":"additional","affiliation":[{"name":"University of Ghent Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng\u2010Chung","family":"Wei","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Pfizer Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Bonin","sequence":"additional","affiliation":[{"name":"Pfizer Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jones","sequence":"additional","affiliation":[{"name":"Pfizer Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Marshall","sequence":"additional","affiliation":[{"name":"Pfizer Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Logeart","sequence":"additional","affiliation":[{"name":"Pfizer International Operations Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Vlahos","sequence":"additional","affiliation":[{"name":"Pfizer Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.","family":"Bukowski","sequence":"additional","affiliation":[{"name":"Pfizer Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"University of Alberta Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370709"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205322"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151563"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087270"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200358"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.078139"},{"key":"e_1_2_8_10_1","first-page":"238","article-title":"Sustained efficacy and safety, including patient\u2010reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"Mart\u00edn\u2010Mola E","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta20090"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38973"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38721"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207596"},{"key":"e_1_2_8_17_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204948"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4244"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:34:13Z","timestamp":1759426453000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1002\/acr.23276"],"URL":"https:\/\/doi.org\/10.1002\/acr.23276","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}